Results published from part 1 of Friedreich’s ataxia drug trial – Ataxia

Results published from part 1 of Friedreich’s ataxia drug trial

Results published from part 1 of Friedreich’s ataxia drug trial

The results from part 1 of a clinical trial investigating a potential therapy for Fredreich’s ataxia have been published. Omaveloxolone, a drug that we reported in July after it gained a new Orphan drug designation for Friedreich’s ataxia with Reata Pharmaceuticals (see here), has been in the process of being tested in 2-part international, multi-centre, randomized, double-blind, placebo-controlled phase 2 trial, referred to as MOXIe.

The results of part 1 of the study were published in the Annals of Clinical and Translational Neurology journal (see here). The study found Omaveloxolone was well tolerated, and adverse events were generally mild. Treatment of Friedreich ataxia patients with omaveloxolone at the optimal dose level of 160 mg/day appeared to improve neurological function.

The investigation is continuing in part two of the trial at various sites around the world including the London ataxia centre. Results from part two of the trial are expected in second half of 2019.

Posted on 23/11/2018


Something went wrong. Please check your entries and try again.
fundraise image


Take part in a challenge or create your fundraiser. Every penny you raise will help those affected by ataxia.

Donate Image


To make either a one off or recurring donation which will help fund research into treatments and cures and supports those affected ataxia

Volunteer Image


Support the ataxia community and volunteer with Ataxia UK. From social media to telephone befriending, there are loads of ways you can make a difference to someone's life.

Donate Now
Welcome to our new site! We hope you like it.
As it's brand new, there may be a few temporary glitches such as broken links - we are working on getting these all fixed ASAP. If you'd like to give us any feedback or let us know if something isn't quite right, please email
Scroll to Top